Journal of Pharmacy and Pharmacology 2010-08-01

PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver.

Motoko Saito-Yabe, Yuji Kasuya, Yasushi Yoshigae, Naotoshi Yamamura, Yukie Suzuki, Nao Fukuda, Masashi Honma, Kazuki Yano, Shin-Ichi Mochizuki, Fumihiko Okada, Akiko Okada, Yuki Nagayama, Eisuke Tsuda, Thomas Fischer, Ursula Höpner, Silvia Zaja, Juergen Mueller, Junichi Okada, Atsushi Kurihara, Toshihiko Ikeda, Osamu Okazaki

Index: J. Pharm. Pharmacol. 62(8) , 985-94, (2010)

Full Text: HTML

Abstract

Our aim was to investigate the effect of PEGylation on the uptake of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) into rat liver, kidney and spleen, and human liver.Copolymer of polyethyleneglycol allylmethylether and maleamic acid sodium salt with OCIF (poly(PEG)-OCIF) (0.5 mg/kg) was administered to rats and the concentrations of poly(PEG)-OCIF in the liver, kidney and spleen at 15 min after administration were measured by ELISA. For human liver uptake, the liver perfusion of OCIF and (3)H-labelled poly(PEG)-OCIF was conducted using fresh human liver block.The tissue uptake of poly(PEG)-OCIF in rats was significantly lower compared with that of OCIF. In fresh human liver perfusion, (3)H-poly(PEG)-OCIF was rarely taken up into the liver. On the other hand, more than 50% of the perfused OCIF was taken up.PEGylation of OCIF using poly(PEG) dramatically suppressed the uptake of OCIF into human liver as well as into rat liver and could be a promising approach for improving the pharmacokinetic and pharmacological effects of OCIF in the clinical setting.